Ogenx Therapeutics Corporation is a clinical stage drug development company dedicated to advancing our platform of 35 Redoxagens for the treatment of numerous disease targets.
The Redoxagens are pro-drugs designed to upregulate redox-mediated mitochondrial signaling that turn on cell self-repair mechanisms. They have been tested in over 300 humans and over 8,000 horses against multiple diseases with profound success and without serious adverse events.
Our principal focus is development of treatments for the Dry form of Age-related Macular Degeneration. Our veterinary subsidiary Ogenx Animal Health is focused on development of treatments against Canine Lymphoma and Mast Cell Tumors and Equine Infectious Diseases.